×
S&P 500   4,131.37 (+1.81%)
DOW   32,996.99 (+1.10%)
QQQ   306.80 (+2.50%)
AAPL   148.38 (+3.20%)
MSFT   270.67 (+1.79%)
FB   193.69 (+1.07%)
GOOGL   2,227.27 (+3.31%)
AMZN   2,265.00 (+1.96%)
TSLA   750.88 (+6.10%)
NVDA   186.37 (+4.40%)
BABA   93.08 (-1.48%)
NIO   16.39 (+2.25%)
AMD   101.11 (+2.39%)
CGC   4.89 (-11.89%)
MU   72.95 (+3.33%)
T   21.21 (-0.52%)
GE   77.87 (+1.12%)
F   13.55 (+3.28%)
DIS   108.29 (+2.54%)
AMC   13.79 (+12.76%)
PFE   53.58 (-0.76%)
PYPL   84.92 (+5.60%)
NFLX   194.13 (+1.43%)
S&P 500   4,131.37 (+1.81%)
DOW   32,996.99 (+1.10%)
QQQ   306.80 (+2.50%)
AAPL   148.38 (+3.20%)
MSFT   270.67 (+1.79%)
FB   193.69 (+1.07%)
GOOGL   2,227.27 (+3.31%)
AMZN   2,265.00 (+1.96%)
TSLA   750.88 (+6.10%)
NVDA   186.37 (+4.40%)
BABA   93.08 (-1.48%)
NIO   16.39 (+2.25%)
AMD   101.11 (+2.39%)
CGC   4.89 (-11.89%)
MU   72.95 (+3.33%)
T   21.21 (-0.52%)
GE   77.87 (+1.12%)
F   13.55 (+3.28%)
DIS   108.29 (+2.54%)
AMC   13.79 (+12.76%)
PFE   53.58 (-0.76%)
PYPL   84.92 (+5.60%)
NFLX   194.13 (+1.43%)
S&P 500   4,131.37 (+1.81%)
DOW   32,996.99 (+1.10%)
QQQ   306.80 (+2.50%)
AAPL   148.38 (+3.20%)
MSFT   270.67 (+1.79%)
FB   193.69 (+1.07%)
GOOGL   2,227.27 (+3.31%)
AMZN   2,265.00 (+1.96%)
TSLA   750.88 (+6.10%)
NVDA   186.37 (+4.40%)
BABA   93.08 (-1.48%)
NIO   16.39 (+2.25%)
AMD   101.11 (+2.39%)
CGC   4.89 (-11.89%)
MU   72.95 (+3.33%)
T   21.21 (-0.52%)
GE   77.87 (+1.12%)
F   13.55 (+3.28%)
DIS   108.29 (+2.54%)
AMC   13.79 (+12.76%)
PFE   53.58 (-0.76%)
PYPL   84.92 (+5.60%)
NFLX   194.13 (+1.43%)
S&P 500   4,131.37 (+1.81%)
DOW   32,996.99 (+1.10%)
QQQ   306.80 (+2.50%)
AAPL   148.38 (+3.20%)
MSFT   270.67 (+1.79%)
FB   193.69 (+1.07%)
GOOGL   2,227.27 (+3.31%)
AMZN   2,265.00 (+1.96%)
TSLA   750.88 (+6.10%)
NVDA   186.37 (+4.40%)
BABA   93.08 (-1.48%)
NIO   16.39 (+2.25%)
AMD   101.11 (+2.39%)
CGC   4.89 (-11.89%)
MU   72.95 (+3.33%)
T   21.21 (-0.52%)
GE   77.87 (+1.12%)
F   13.55 (+3.28%)
DIS   108.29 (+2.54%)
AMC   13.79 (+12.76%)
PFE   53.58 (-0.76%)
PYPL   84.92 (+5.60%)
NFLX   194.13 (+1.43%)
LON:INS

Instem (INS) Share Forecast, Price & News

GBX 687.50
+5.00 (+0.73%)
(As of 05/27/2022 04:19 PM ET)
Add
Compare
Today's Range
684.40
▼
700
50-Day Range
621
▼
815.68
52-Week Range
555
▼
910
Volume
12,549 shs
Average Volume
28,436 shs
Market Capitalization
£155.90 million
P/E Ratio
92.91
Dividend Yield
N/A
Beta
N/A
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive INS News and Ratings via Email

Sign-up to receive the latest news and ratings for Instem and its competitors with MarketBeat's FREE daily newsletter.

Instem logo

About Instem

Instem plc, together with its subsidiaries, provides information technology applications to the life sciences healthcare market worldwide. The company offers solutions for data collection, management, and analysis to meet the needs of life science and healthcare organizations for data-driven decision making. Its solutions include ALPHADAS, an eSource EDC system for early phase clinical trials; BioRails for discovery data management; Comet Assay IV, a live video imaging system for reproducible comet slide scoring; and Cyto Study Manager, a data acquisition and reporting solution. The company also offers computational toxicology products and services; Logbook, a repository for information; Morphit for discovery data visualization; NOTOCORD-hem software platforms to acquire, display, and analyze physiological signals; and Provantis, a Windows-based system for organizations and universities in non-clinical evaluation studies. In addition, the company provides Samarind RMS to manage medical product information; submit platform that offers tools and services for the creation and management of SEND datasets and associated documents for contract research organizations and sponsors; SENDView, an application that simplifies the review of SEND datasets; SEND Explorer, a web-based application with optional data warehousing capabilities; SENDTrial, a Web based solution that can be accessed through a subscription; and standard for exchange of nonclinical data solutions. Further, it provides Sorcerer Colony Counter for automatic plate counter; anonymization, cloud, validation, and safety assessment and regulatory information management software services; and software solutions to extract intelligence from research and development related healthcare data. Additionally, the company develops, manufactures, and supplies software and hardware products for in vitro study data collection and management. Instem plc was founded in 1969 and is headquartered in Stone, the United Kingdom.

Headlines

May 27, 2022 | americanbankingnews.com
Instem (LON:INS) Stock Price Passes Below 200-Day Moving Average of $751.21
May 27, 2022 | americanbankingnews.com
Instem (LON:INS) Stock Price Crosses Below 200-Day Moving Average of $751.21
May 14, 2022 | finance.yahoo.com
Instem (LON:INS) shareholders have earned a 27% CAGR over the last five years
May 13, 2022 | benzinga.com
Global Drug Discovery Software market valued at $2 billion in 2020, is expected to grow at a CAGR of 14% to cross $3.5 billion by 2025
May 10, 2022 | finance.yahoo.com
Instem Awarded EMA Research Grant
May 10, 2022 | americanbankingnews.com
Instem (LON:INS) Stock Price Passes Below Two Hundred Day Moving Average of $765.60
May 4, 2022 | proactiveinvestors.com
Instem research consortium lands €2.5mln European Medicines Agency grant
May 3, 2022 | lse.co.uk
Instem secures European Medicines Agency research grant
April 26, 2022 | lse.co.uk
TOP NEWS SUMMARY: Musk champions free speech as takes Twitter private
April 26, 2022 | marketwatch.com
Instem Shares Fall as 2022 Expectations Hit by Wage Inflation
March 14, 2022 | uk.finance.yahoo.com
Global Life Sciences Software market is valued at $11 billion in 2020 and is expected to grow at a CAGR of 11% to reach $18 billion by 2025
February 12, 2022 | finance.yahoo.com
Is There An Opportunity With Instem plc's (LON:INS) 47% Undervaluation?
December 14, 2021 | finance.yahoo.com
Are Instem plc's (LON:INS) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
See More Headlines

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Healthcare Information Services
Sub-Industry
N/A
Sector
Computer and Technology
Current Symbol
LON:INS
Previous Symbol
CUSIP
N/A
CIK
N/A
Web
www.instem.com
Phone
+44-1785-825600
Fax
N/A
Employees
480
Year Founded
N/A

Sales & Book Value

Annual Sales
£46.02 million
Price / Sales
3.39
Cash Flow
GBX 69.46 per share
Price / Cash Flow
9.90
Book Value
GBX 214.60 per share
Price / Book
3.20

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
4.92
Current Ratio
0.93
Quick Ratio
0.93

Price-To-Earnings

Trailing P/E Ratio
92.91
Forward P/E Ratio
20.50
P/E Growth
1.96

Miscellaneous

Outstanding Shares
22,677,000
Free Float
N/A
Market Cap
£155.90 million
Optionable
Not Optionable

MarketRank™

Overall MarketRank™

0.69 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -













Instem (LON:INS) Frequently Asked Questions

Who are Instem's key executives?
Instem's management team includes the following people:
  • Mr. Phil J. Reason, CEO & Exec. Director (Age 60, Pay $276k)
  • Mr. Nigel John Goldsmith, CFO, Sec. & Exec. Director (Age 60, Pay $153k)
  • Ms. Marybeth Thompson, Chief Operating Officer
  • Dr. Gordon Smith Baxter, Chief Scientific Officer
  • Mr. Vince D'Angelo, VP of Governance, Risk Management & Compliance
  • Mr. Gary Mitchell, VP of Global Marketing
  • Mr. Adrian Gare, VP of Corp. Devel.
  • Ms. Eve Leconte, Head of People Services
  • Mr. Mike Harwood, Exec. VP of Regulatory eStudy Solutions
  • Mr. Gregor Grant, Exec. VP of Preclinical Solutions
What other stocks do shareholders of Instem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Instem investors own include Abeona Therapeutics (ABEO), ARCA biopharma (ABIO), Apollo Investment (AINV), Alico (ALCO), Corindus Vascular Robotics (CVRS), Delta Apparel (DLA), DSS (DSS), Evans Bancorp (EVBN), The LGL Group (LGL) and UQM Technologies (UQM).

What is Instem's stock symbol?

Instem trades on the London Stock Exchange (LON) under the ticker symbol "INS."

How do I buy shares of Instem?

Shares of INS and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Instem's stock price today?

One share of INS stock can currently be purchased for approximately GBX 687.50.

How much money does Instem make?

Instem has a market capitalization of £155.90 million and generates £46.02 million in revenue each year.

How many employees does Instem have?

Instem employs 480 workers across the globe.

What is Instem's official website?

The official website for Instem is www.instem.com.

How can I contact Instem?

Instem's mailing address is Diamond Way, Stone Business Park, STONE, ST15 0SD, United Kingdom. The company can be reached via phone at +44-1785-825600.

This page was last updated on 5/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.